Cubic magnetically guided nanoaggregates for inhalable drug delivery: In vitro magnetic aerosol deposition study

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 977-993

  Ragab, Doaa Mohamed ^a,b   Rohani, Sohrab ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

in vitro aerosol deposition; magnetic nanoaggregates; magnetic next generation impinger; polyrotaxane; saturation magnetization

Indexed keywords

AMINE; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; COPOLYMER; CUBIC MAGNETICALLY GUIDED NANOAGGREGATE; DRUG CARRIER; MAGNETIC NANOPARTICLE; POLY(PROPYLENE GLYCOL) BIS(2 AMINOPROPYLETHER); POLYROTAXANE; ROTAXANE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRY POWDER; DRY POWDER INHALER; IN VITRO STUDY; MAGNETIC FIELD; MATERIAL COATING; MATHEMATICAL MODEL; MORPHOLOGY; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; MAGNETICS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES;

EID: 84890177433     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9980-y     Document Type: Article

References (48)

1. Brzoska M, Langer K, Coester C, Loitsch S, Wagner TOF, Mallinckrodt C. Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun. 2004;318(2):562-70.
2. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25(4-5):427-37.
3. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine (Lond). 2006 Aug;1(2):157-68.
4. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond). 2007 Feb;2(1):23-39.
5. Arias JL, Gallardo V, Gómez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Controlled Release. 2001;77(3):309-21.
6. Stahlhofen W, Moller W. Behaviour of magnetic micro-particles in the human lung. Radiat Environ Biophys. 1993;32(3):221-38.
7. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol. 2004 Sep;11(9):996-1004.
8. Pauwels EK, Erba P. Towards the use of nanoparticles in cancer therapy and imaging. Drug News Perspect. 2007 May;20(4):213-20.
9. Bamrungsap S, Chen T, Shukoor MI, Chen Z, Sefah K, Chen Y, et al. Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles. ACS Nano. 2012;6(5):3974-81.
10. Lewin M, Carlesso N, Tung C, Tang X, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotech. 2000;18(4):410-4.
11. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404-7.
12. Hua MY, Yang HW, Liu HL, Tsai RY, Pang ST, Chuang KL, et al. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials. 2011 Dec;32(34):8999-9010.
13. Lam JK, Liang W, Chan H. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. 2012;64(1):1-15.
14. Pankhurst QA, Thanh NTK, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J Phys D. 2009;42(22):224001.
15. McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond). 2007 Apr;2(2):153-67.
16. Zhang JL, Srivastava RS, Misra RD. Core-shell magnetite nanoparticles surface encapsulated with smart stimuli-responsive polymer: synthesis, characterization, and LCST of viable drug-targeting delivery system. Langmuir. 2007;23(11):6342-51.
17. Bogdanov Jr AA, Martin C, Weissleder R, Brady TJ. Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes. Biochim Biophys Acta. 1994 Jul 13;1193(1):212-8.
18. Bulte JW, De Cuyper M. Magnetoliposomes as contrast agents. Methods Enzymol. 2003;373:175-98.
19. Tomitaka A, Koshi T, Hatsugai S, Yamada T, Takemura Y. Magnetic characterization of surface-coated magnetic nanoparticles for biomedical application. J Magn Magn Mater. 2011;323(10):1398-403.
20. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995-4021.
21. Walter JG, Petersen S, Stahl F, Scheper T, Barcikowski S. Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers. J Nanobiotechnology 2010;8:21-3155-8-21.
22. Ragab DM, Rohani S, Consta S. Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates. Int J Nanomedicine. 2012;7:3167-89.
23. Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010 Sep;31(25):6574-81.
24. Siegwart DJ, Srinivasan A, Bencherif SA, Karunanidhi A, Oh JK, Vaidya S, et al. Cellular uptake of functional nanogels prepared by inverse miniemulsion ATRP with encapsulated proteins, carbohydrates, and gold nanoparticles. Biomacromolecules. 2009;10(8):2300-9.
25. Harada A, Okada M, Li J, Kamachi M. Preparation and characterization of inclusion complexes of poly(propylene glycol) with cyclodextrins. Macromolecules. 1995;28(24):8406-11.
26. Zhou Y, Wang H, Wang C, Li Y, Lu W, Chen S, et al. Receptor-mediated, tumor-targeted gene delivery using folate-terminated polyrotaxanes. Mol Pharmaceutics. 2012;9(5):1067-76.
27. Moghimi SM, Hedeman H, Christy NM, Illum L, Davis SS. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J Leukoc Biol 54:513-7.
28. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
29. Mykhaylyk O, Dudchenko N, Dudchenko A. Doxorubicin magnetic conjugate targeting upon intravenous injection into mice: high gradient magnetic field inhibits the clearance of nanoparticles from the blood. J Magn Magn Mater. 2005;293(1):473-82.
30. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60(8):863-75.
31. Xie Y, Longest PW, Xu YH, Wang JP, Wiedmann TS. In vitro and in vivo lung deposition of coated magnetic aerosol particles. J Pharm Sci. 2010;99(11):4658-68.
32. Ohno H, Yoshizawa M, Ogihara W. Development of new class of ion conductive polymers based on ionic liquids. Electrochim Acta. 2004;50(2-3):255-61.
33. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Controlled Release. 2001;70(3):329-39.
34. Hoe S, Young PM, Chan HK, Traini D. Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharmaceut Res 2009;26:431-7.
35. Hoe S, Traini D, Chan HK, Young P. Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). Eur J Pharm Sci. 2009;38:88-94.
36. Behara SRB, Larson I, Kippax P, Morton DAV, Stewart P. An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology. Chem Eng Sci. 2011;66(8):1640-8.
37. Suzaki Y, Murata S, Osakada K. Ferrocene-containing side chain polyrotaxanes obtained by radical copolymerization of styrenes with acrylamide with a 2]rotaxane structure. Chem Lett. 2009;38(4):356-7.
38. Zhen G, Muir BW, Moffat BA, Harbour P, Murray KS, Moubaraki B, et al. Comparative study of the magnetic behavior of spherical and cubic superparamagnetic iron oxide nanoparticles. J Phys Chem C. 2011;115(2):327-34.
39. Song Q, Zhang ZJ. Shape control and associated magnetic properties of spinel cobalt ferrite nanocrystals. J Am Chem Soc. 2004;126(19):6164-8.
40. Parsons JG, Luna C, Botez CE, Elizalde J, Gardea-Torresdey JL. Microwave assisted synthesis of iron(III) oxyhydroxides/oxides characterized using transmission electron microscopy, X-ray diffraction, and X-ray absorption spectroscopy. J Phys Chem Solids. 2009;70(3):555-60.
41. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle performance. J Pharm Sci. 2012;101(3):1097-107.
42. Mitchell JP, Nagel MW, Wiersema KJ, Doyle CC. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. AAPS PharmSciTech. 2003 Oct 22;4(4):E54.
43. Hori H, Yamamoto Y, Iwamoto T, Miura T, Teranishi T, Miyake M. Diameter dependence of ferromagnetic spin moment in Au nanocrystals. PhysRevB. 2004;69(17):174411.
44. He L. Comment on "Diameter dependence of ferromagnetic spin moment in Au nanocrystals". PhysRevB. 2010;81(9):096401.
45. Coates MS, Chan HK, Fletcher DF, Raper JA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005 Sep;22(9):1445-53.
46. Coates MS, Chan HK, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size. J Pharm Sci. 2006 Jun;95(6):1382-92.
47. Lee C, Kramer TA. Prediction of three-dimensional fractal dimensions using the two-dimensional properties of fractal aggregates. Adv Colloid Interface Sci. 2004;112(1-3):49-57.
48. Kendall K, Kosseva MR. Nanoparticle aggregation influenced by magnetic fields. Colloids Surf Physicochem Eng Aspects. 2006;286(1-3):112-6.